Sanofi US does not review the information
contained on this website and/or database
for content, accuracy or completeness. Use
of and access to this information is subject to
the terms, limitations and conditions set by the
website and/or database producer.
This site might not comply with the regulatory requirements of US
「Room 7」（3F 234）, Building No. 2,
Nagoya Congress Center
Suppression of Type 2 Inflammation
Ken Igawa M.D., Ph.D.
Professor, Department of Dermatology, Dokkyo Medical University, School of Medicine
“Atopic dermatitis; its treatment goal and disease burden”
Koji Masuda M.D., Ph.D.
Associate Professor, Department of Dermatology, Kyoto Prefectural University of Medicine
“Role of cytokine signal and atopic dermatitis”
Masato Kubo Ph.D.
Professor, Division of Molecular Pathology Research Institute for Biomedical Sciences Tokyo University of Science
Laboratory head, Laboratory for cytokine regulation, Center for Integrated Medical Science, RIKEN Yokohama Institute
Hidehisa Saeki M.D., Ph.D.
Professor, Department of Dermatology, Nippon Medical School
“Importance of maintaining long-term remission for AD patients”
Akio Tanaka M.D., Ph.D.
Associate Professor, Department of Dermatology,
Graduate School of Biomedical and Health Sciences, Hiroshima University
“Treatment strategy to achieve long-term control (LTC) of atopic dermatitis”
Yoko Kataoka M.D.
Chief Director, Department of Dermatology,
Osaka Habikino Medical Center, Habikino, Osaka